Treatment of metastatic castration-resistant prostate cancer (mCRPC). Approved for use in: Chemo-naive setting: Patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy. Post-docetaxel setting: Patients whose disease has progressed during or after chemotherapy.

Dosage and administration

Recommended Dose: 160 mg orally once daily. ⚠️ Pill Count: Each capsule contains 40 mg. You must take 4 capsules at the same time to reach the 160 mg dose. Administration: Can be taken with or without food. Swallow capsules whole with water. Do not chew, dissolve, or open them.

Seizure History: Use with caution in patients with a history of seizures, underlying brain injury, stroke, or brain tumors. Hypersensitivity to Enzalutamide. Women who are or may become pregnant (Teratogenic risk).

The most common adverse reaction is fatigue (asthenia). Other potential side effects: Hot flashes. Headache. Hypertension (High blood pressure). Falls and Fractures (due to dizziness or weakness). Seizure Warning: Permanently discontinue Indenza in patients who develop a seizure during treatment.

Indenza — Enzalutamide 40 mg, 112 pcs, Aprazer

100% original product

Active ingredient

Enzalutamide

Manufacturer

Aprazer

Dosage 40 mg

Dosage form Capsules

Capsules per pack 112

Indenza — Enzalutamide 40 mg

Name: Indenza
Brand: Aprazer
SKU: PROD-19
Price: 8526 UAH
Availability: InStock

8526₴ ~~9669₴~~ -12%

Indenza is an advanced androgen receptor inhibitor for prostate cancer treatment. Active ingredient: Enzalutamide (40 mg).

Manufacturer: Aprazer Healthcare (India). It is a high-quality generic equivalent of Xtandi.

Mechanism:

Indenza acts on three different steps in the androgen receptor signaling pathway. Unlike older anti-androgens, it creates a complete blockade, preventing cancer cells from using testosterone to grow.

✅ Patient Benefit: Offers a convenient oral therapy without the need for concurrent steroid (prednisone) use, reducing steroid-related toxicity.

Treatment of metastatic castration-resistant prostate cancer (mCRPC).

Approved for use in:

Chemo-naive setting: Patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy.
Post-docetaxel setting: Patients whose disease has progressed during or after chemotherapy.

Recommended Dose: 160 mg orally once daily.

⚠️ Pill Count:

Each capsule contains 40 mg.
You must take 4 capsules at the same time to reach the 160 mg dose.

Administration: Can be taken with or without food. Swallow capsules whole with water. Do not chew, dissolve, or open them.

Seizure History: Use with caution in patients with a history of seizures, underlying brain injury, stroke, or brain tumors.
Hypersensitivity to Enzalutamide.
Women who are or may become pregnant (Teratogenic risk).

The most common adverse reaction is fatigue (asthenia).

Other potential side effects:

Hot flashes.
Headache.
Hypertension (High blood pressure).
Falls and Fractures (due to dizziness or weakness).

Seizure Warning: Permanently discontinue Indenza in patients who develop a seizure during treatment.

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 01.04.2026